A Phase 4 interventional study of fractional carbon dioxide laser and Tazarotene Cream 0.1% in Nail Psoriasis, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Assiut University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Psoriasis by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Psoriasis · Assiut University.
Among the 19 studies in Psoriasis by Assiut University, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2017, is one of 5 in phase 4, and was the 1st registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →7 of the 19 studies in Psoriasis by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 6+
Assiut University
Ages 18+
Assiut University
Ages 18–60
Assiut University
Ages 18–60
By country, each count listing its studies:
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 30 across the 10 interventional studies, 75 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,188 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Psoriasis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07366268Assiut UniversityEvaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis | 2027-05 |
| NCT07495657Assiut UniversityPre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Psoriasis by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nail psoriasis has a high incidence amongst patients with psoriasis.It is estimated to affect 80% of psoriatic patients at some time during their lives and has a significant adverse influence on their quality of life.
Treatment of nail psoriasis is disappointing, as it is refractory to treatment, with conventional therapies often having little effect.
The characteristic lesions affecting the nail present as 'oil drop' discoloration, splinter haemorrhages, subungual hyperkeratosis, and onycholysis in the nail bed or pitting, leuconychia, erythema of the lunula and crumbling in the nail matrix.Diagnosis is customarily made by patient history and physical examination, though it may be necessary to rule out onychomycosis as a differential diagnosis.
The nail psoriasis severity index has recently been reported as a possible reproducible, objective, and simple tool for clinical assessment of psoriatic nail disease.
The modified target nail psoriasis severity index has been proposed for target nail assessment which would give a degree of gradation for each parameter of 0 to 3 (0 = none, 1 = mild, 2 = moderate, and 3 = severe) in each quadrant.The topical therapies include topical and intralesional corticosteroids , topical vitamin D3 analogues (calcipotriol) , topical tacrolimus and tazarotene[8]. The efficacy of these topical therapies in nail disease is limited mainly by the impenetrability or low penetrability of the nail and nail matrix. In patients with nail psoriasis that is resistant to topical therapies, conventional systemic therapies (e.g., phototherapy, retinoids, cyclosporine, methotrexate) have been shown to be partially effective. More recently, biological therapies (e.g., infliximab, adalimumab, alefacept, etanercept) have proven efficacy in psoriasis and psoriatic arthritis, and some are effective in treating nail disease in patients with psoriasis .
Previous study proved successful treatment of onychodystrophy using fractional carbon dioxide laser with topical steroid. Fractional Carbon dioxide laser might be an effective therapy for nail psoriasis due to its ablative ability which produce microscopic holes that perhaps improve topical drug delivery. Moreover it was hypothesized that tissue ablation and remodelling process stimulate rejuvenation of the abnormal nail bed.The investigators hypothesized that the combination of Fractional carbon dioxide laser and topical tazarotene treatment will have a higher therapeutic effect on nail psoriasis through multiple mechanism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
fractional carbon dioxide laser plus tazarotene 0.1% cream
Device: fractional carbon dioxide laser · Drug: Tazarotene Cream 0.1%
Tazarotene Cream 0.1%
Drug: Tazarotene Cream 0.1%
One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
tazarotene cream 0.1% once daily
percentage of clinically improved patients using modified nail psoriasis severity index.
clinical assessment using modified nail psoriasis severity index.
Time frame: three months
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2017; primary completion for Oct 2018, 12 months later.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 12 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.